Promising Results for GLP-1 Receptor Agonists in Reducing Chronic Migraine Frequency
A pilot study reveals that GLP-1 receptor agonists, such as liraglutide, may significantly reduce the frequency of chronic migraines, offering new hope for treatment-resistant patients.
Migraines affect approximately 15% of people worldwide, often leading to significant discomfort and disruption in daily life. While multiple treatments are available, some individuals do not find relief, or they experience adverse side effects that limit their options. Recent research introduces a novel approach using medications known as GLP-1 receptor agonists—drugs typically used for weight loss and diabetes management—as potential migraine therapeutics.
A pilot study conducted by Italian researcher Simone Braca and colleagues explored the effects of liraglutide, a GLP-1 receptor agonist, on individuals suffering from chronic migraines coupled with obesity. Over a 12-week period, 31 participants (mostly female) received liraglutide and documented their headache frequency. The findings revealed a substantial decrease in migraine days—reducing from an average of about 20 days per month to 11 days after treatment.
Approximately half of the participants experienced a 50% reduction in migraine frequency, with some showing even higher improvements—seven individuals saw up to a 75% decrease, and one participant became migraine-free. Mild gastrointestinal side effects such as nausea and constipation were reported but resolved without impacting the study.
Interestingly, the study indicated that weight loss was not the primary factor behind the migraine relief, as participants’ BMI remained largely unchanged. The researchers hypothesize that liraglutide may influence intracranial pressure (ICP), a known factor in migraine severity, although direct measurements were not taken in the study. Future research aims to clarify the mechanism at play.
This pioneering research opens new avenues for treating chronic migraines, especially in cases resistant to traditional therapies. While more extensive studies are necessary, these early results suggest that GLP-1 receptor agonists like liraglutide could become valuable tools in managing this debilitating condition.
source: https://medicalxpress.com/news/2025-07-ozempic-drug-significantly-frequency-chronic.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Advances in Diagnosing and Treating NUT Carcinoma: New Insights from Dana-Farber Study
New research from Dana-Farber highlights improved diagnostic methods for NUT carcinoma, an aggressive and often underdiagnosed cancer, emphasizing early detection and targeted testing for better patient outcomes.
Innovative Space-Based Study Unveils New Insights into Alzheimer's Protein Aggregation
Space experiments aboard the ISS have enabled the detailed structural analysis of Alzheimer's-related amyloid β fibrils, revealing new pathways in disease progression and showcasing the crucial role of microgravity in biomedical research.
Innovative At-Home Diagnostic Test Enhances Detection of COVID-19 and Cancer with Unprecedented Accuracy
A new at-home biosensing technology utilizing the coffee-ring effect, plasmonic nanoparticles, and AI offers rapid and highly sensitive detection of COVID-19 and cancer biomarkers, paving the way for accessible disease diagnostics.
Addressing Gender Disparities in Stroke Detection by Paramedics: A Path to Saving Lives and Reducing Healthcare Costs
Innovative research reveals that paramedics are less likely to recognize stroke in women, especially with atypical symptoms. Closing this gap can save lives, improve recovery, and cut healthcare costs significantly.